Incannex Healthcare Ltd ADR (IXHL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Incannex Healthcare Ltd ADR (IXHL) has a cash flow conversion efficiency ratio of -0.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($75.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Incannex Healthcare Ltd ADR balance sheet independence to measure how much of total assets are equity-financed.
Incannex Healthcare Ltd ADR - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Incannex Healthcare Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Incannex Healthcare Ltd ADR's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Incannex Healthcare Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Incannex Healthcare Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baan Rock Garden Public Company Limited
BK:BROCK
|
0.001x |
|
AlphaTime Acquisition Corp Ordinary Shares
NASDAQ:ATMC
|
-0.001x |
|
Penguen Gida Sanayi AS
IS:PENGD
|
0.009x |
|
Wiable Corp
KQ:065530
|
0.039x |
|
Bedmutha Industries Limited
NSE:BEDMUTHA
|
0.164x |
|
LFE Corporation Bhd
KLSE:7170
|
0.026x |
|
KCI Limited
KQ:036670
|
0.005x |
|
Visi Media Asia Tbk
JK:VIVA
|
0.067x |
Annual Cash Flow Conversion Efficiency for Incannex Healthcare Ltd ADR (2006–2025)
The table below shows the annual cash flow conversion efficiency of Incannex Healthcare Ltd ADR from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see IXHL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $13.39 Million | $-12.51 Million | -0.935x | +33.84% |
| 2024-06-30 | $11.22 Million | $-15.85 Million | -1.413x | -173.67% |
| 2023-06-30 | $31.34 Million | $-16.18 Million | -0.516x | -44.56% |
| 2022-06-30 | $36.00 Million | $-12.85 Million | -0.357x | +66.51% |
| 2021-06-30 | $6.44 Million | $-6.87 Million | -1.066x | +40.42% |
| 2020-06-30 | $2.17 Million | $-3.89 Million | -1.789x | -133.91% |
| 2019-06-30 | $-418.90K | $-2.21 Million | 5.277x | -32.23% |
| 2018-06-30 | $-385.29K | $-3.00 Million | 7.786x | -51.05% |
| 2017-06-30 | $-169.45K | $-2.70 Million | 15.904x | +1629.81% |
| 2016-06-30 | $-700.36K | $-643.93K | 0.919x | +134.14% |
| 2015-06-30 | $478.47K | $-1.29 Million | -2.693x | -1299.64% |
| 2014-06-30 | $1.74 Million | $390.60K | 0.224x | +163.32% |
| 2013-06-30 | $13.55 Million | $-4.80 Million | -0.355x | -6.14% |
| 2012-06-30 | $20.10 Million | $-6.71 Million | -0.334x | -71.39% |
| 2011-06-30 | $15.23 Million | $-2.97 Million | -0.195x | -37.01% |
| 2010-06-30 | $12.29 Million | $-1.75 Million | -0.142x | +48.14% |
| 2009-06-30 | $6.58 Million | $-1.80 Million | -0.274x | -20.98% |
| 2008-06-30 | $9.51 Million | $-2.16 Million | -0.227x | -305.31% |
| 2007-06-30 | $6.64 Million | $-371.63K | -0.056x | +6.01% |
| 2006-06-30 | $1.34 Million | $-79.83K | -0.060x | -- |
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more